{"Clinical Trial ID": "NCT00471276", "Intervention": ["INTERVENTION 1:", "- Sunitinib", "Unitinib 37.5 milligrams (mg) per day per oral capsule in continuous daily dose (CDD). Dose adjustments, if necessary, included a reduction to 25 mg per day or an increase to 50 mg per day at any time after week 12."], "Eligibility": ["Incorporation criteria:", "A diagnosis of histologically or cytologically proven breast cancer", "A local metastatic or recurrent disease which, in the opinion of the investigator, is not suitable for resection or radiotherapy", "* Patients with at least one measurable injury according to RECIST", "- Exclusion criteria:", "Inflammatory breast cancer", "Previous treatment with VEGF inhibitors (unless adjuvant treatment has taken place at least 12 months ago)"], "Results": ["Performance measures:", "Number of participants with an objective response", "Number of participants with an objective assessment based on the response of the confirmed complete response (CR) or confirmed partial response (PR) according to the criteria for assessing response in solid tumours (RCIST). RC defined as the disappearance of all target lesions. PR defined as a decrease greater than or equal to 30 percent (30%) of the sum of the longest dimensions of target lesions taking as reference the reference sum of the longest dimensions.", "Time frame: Baseline, week 9, and every 8 weeks to month 34", "Results 1:", "Title of the arm/group: Sunitinib", "Description of the arm/group: Sunitinib 37.5 milligrams (mg) per day per oral capsule as a continuous daily dose (CDD). Dose adjustments, if necessary, included a reduction to 25mg per day or an increase to 50mg per day at any time after week 12.", "Total number of participants analysed: 83", "Type of measurement: Number", "Unit of measure: Participants 7"], "Adverse Events": ["Undesirable Events 1:", "Total: 13/83 (15.66%)", "Congestive heart failure 1/83 (1.20%)", "Hypothyroidism 1/83 (1.20%)", "Nausea 2/83 (2.41%)", "- Vomiting 2/83 (2.41%)", "Diarrhoea 1/83 (1.20 %)", "gastrointestinal haemorrhage 1/83 (1.20%)", "Asthenia 1/83 (1.20%)", "1/83 (1.20%)", "Anal abscesses 1/83 (1.20%)", "Dehydration 3/83 (3.61%)", "Decreased appetite 1/83 (1.20%)"]}